|Bid||154.00 x 0|
|Ask||160.00 x 0|
|Day's Range||155.85 - 159.40|
|52 Week Range||101.80 - 164.70|
|Beta (3Y Monthly)||0.70|
|PE Ratio (TTM)||103.02|
|Earnings Date||Aug 8, 2019|
|Forward Dividend & Yield||2.00 (1.26%)|
|1y Target Est||163.00|
ST. GALLEN, Switzerland & HAMBURG, Germany-- -- Vifor Pharma and Evotec to create a jointly-owned drug discovery and development platform for innovative nephrology therapeutics Collaboration brings together Evotec’s best-in-class drug discovery capabilities and Vifor Pharma’s development and commercialization expertise in nephrology Joint venture will focus on patient data driven target identification ...
ST GALLEN, Switzerland-- -- Agreement to jointly commercialise the new diabetic kidney disease indication for INVOKANA ® in the US Only diabetes treatment indicated to slow down the progression of DKD in type 2 diabetes patients since the standard of care was developed nearly 20 years ago, while also reducing the risk of heart failure hospitalizations Using its US salesforce to promote INVOKANA ® to ...
Likewise, there is a lack of experts with the necessary specialist knowledge – and these experts are urgently needed in industry, at regulatory authorities and in medical practice, including in Switzerland. As with other areas of cutting-edge research, this will take the form of a global race: those able to present findings as quickly as possible will be able to assert themselves as a centre of excellence in nanopharmaceutics.
Vifor Pharma today announced that treatment of the first patient in their global phase-IIIb DIAMOND study has begun. The study will evaluate the potential of Veltassa® to improve outcomes by enabling heart failure (HF) patients, with or without chronic kidney disease (CKD), to be treated with renin-angiotensin-aldosterone system inhibitors (RAASi) therapy in accordance with HF treatment guidelines1,2. Presently, RAASi treatment is frequently discontinued due to the risk of hyperkalaemia (elevated blood potassium levels).
ZURICH-- -- Veltassa ® enables spironolactone for blood pressure management in patients with resistant hypertension and chronic kidney disease by controlling blood potassium levels. Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190510005469/en/ Vifor Pharma today announced results from the phase-II AMBER study which demonstrated ...
ZURICH-- -- Shareholders agreed to the Board of Directors’ recommendations for all proposed resolutions Election of Dr. Sue Mahony and Kim Stratton and to the Board of Directors Confirmation of all members of the Board of Directors standing for re-election Dividend of CHF 2.00 approved Regulatory News: At the 91 st Annual Shareholder Meeting of Vifor Pharma Ltd., shareholders approved all proposed ...
The Vifor Pharma Group (VIFN.VX) and Akebia Therapeutics, Inc. (AKBA) today announced that the companies have amended the terms of their license agreement to sell vadadustat to Fresenius Medical Care North America dialysis clinics in the United States, subject to its approval by the U.S. Food and Drug Administration (FDA). Under the terms of the agreement signed in May 2017, Akebia granted Vifor Pharma a license to sell vadadustat to Fresenius Medical Care North America for use solely within its dialysis clinics in the U.S., subject to FDA approval.